Finance ❯ Stock Market

Pharmaceutical Stocks

Market Reactions Eli Lilly Novo Nordisk Market Performance Novo Nordisk Shares Eli Lilly Stock Company Performance Investor Sentiment Market Trends Novo Nordisk Stock Eli Lilly Stock Performance Technical Analysis Vertex Pharmaceuticals Psychedelic Companies Roche Alembic Pharmaceuticals Kymera Therapeutics GoodRx Holdings Sarepta Therapeutics Stock Vaccine Developers ARWR Stock Performance Valneva Stocks Eli Lilly Investments Novo Nordisk Stock Performance Eli Lilly (LLY) Investor Confidence Investment Analysis Regeneron Pharmaceuticals

CVS Caremark Reverses Exclusion and Adds Lilly’s Foundayo and Zepbound to Its Formulary

Formulary parity across the three largest U.S. PBMs will expand insured access to Lilly’s obesity drugs.

FDA Grants Accelerated Approval to Kresladi, First Gene Therapy for Severe Pediatric LAD-1

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

FDA Warns 30 Telehealth Firms Over Misleading Ads for Compounded GLP-1 Drugs

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

FDA Clears Arrowhead’s Redemplo for FCS, Marking the Biotech’s First Approval